598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)

598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)

Bibliographic Details
Main Authors: Michael Chisamore, Noelly Madeleine, Austin Rayford, Gro Gausdal, David R Micklem, Magnus Blø, Dina Alzhanova, Josephine Amalia Taverna, Chia-Nung Hung, Rolf A Brekken, Claudia Gorcea-Carson, Cristina Oliva, Nigel McCracken
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items